BR112012009801A8 - Polipeptídeo neurturina e variante de neurturina - Google Patents
Polipeptídeo neurturina e variante de neurturinaInfo
- Publication number
- BR112012009801A8 BR112012009801A8 BR112012009801A BR112012009801A BR112012009801A8 BR 112012009801 A8 BR112012009801 A8 BR 112012009801A8 BR 112012009801 A BR112012009801 A BR 112012009801A BR 112012009801 A BR112012009801 A BR 112012009801A BR 112012009801 A8 BR112012009801 A8 BR 112012009801A8
- Authority
- BR
- Brazil
- Prior art keywords
- neurturin
- variant
- polypeptide
- polypeptides
- nucleic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
Abstract
POLIPEPTÍDEO NEURTURINA E VARIANTE DE NEURTURINA. Polipeptídeos neurturina gue possuem afinidade de ligação reduzida com heparina e sulfato de heparano, mas que retém a atividade neurotrófica; ácidos nucleicos que codificam as variantes neurturina e vetores e células hospedeiras que expressam os polipeptídeos neurturina aprimorados. Utilização de polipeptídeos neurturina aprimorados, ácidos nucleicos e células hospedeiras no tratamento ou na prevenção de doenças.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25635209P | 2009-10-30 | 2009-10-30 | |
PCT/US2010/054419 WO2011053675A2 (en) | 2009-10-30 | 2010-10-28 | Improved neurturin molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012009801A2 BR112012009801A2 (pt) | 2016-08-09 |
BR112012009801A8 true BR112012009801A8 (pt) | 2016-08-30 |
Family
ID=43922977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012009801A BR112012009801A8 (pt) | 2009-10-30 | 2010-10-28 | Polipeptídeo neurturina e variante de neurturina |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP2774935B8 (pt) |
JP (1) | JP2013509422A (pt) |
CN (1) | CN102695723A (pt) |
AU (1) | AU2010313456A1 (pt) |
BR (1) | BR112012009801A8 (pt) |
CA (1) | CA2778678A1 (pt) |
ES (1) | ES2632431T3 (pt) |
NZ (1) | NZ599543A (pt) |
WO (1) | WO2011053675A2 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012267519A1 (en) * | 2011-06-09 | 2014-01-09 | University Of Miami | Methods of treatment for retinal diseases |
FR3093640B1 (fr) * | 2019-03-15 | 2021-10-01 | Biophytis | Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement de maladies neuromusculaires |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4409331A (en) | 1979-03-28 | 1983-10-11 | Damon Corporation | Preparation of substances with encapsulated cells |
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4542025A (en) | 1982-07-29 | 1985-09-17 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
US4684479A (en) | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
US4829000A (en) | 1985-08-30 | 1989-05-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Reconstituted basement membrane complex with biological activity |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US6759057B1 (en) | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
AU598958B2 (en) | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5110596A (en) | 1988-12-13 | 1992-05-05 | Alza Corporation | Delivery system comprising means for delivering agent to livestock |
US5034229A (en) | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
ATE133087T1 (de) | 1989-05-04 | 1996-02-15 | Southern Res Inst | Einkapselungsverfahren |
US6517859B1 (en) | 1990-05-16 | 2003-02-11 | Southern Research Institute | Microcapsules for administration of neuroactive agents |
US5215680A (en) | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
DE4137649C2 (de) | 1991-11-15 | 1997-11-20 | Gerhard Dingler | Bauelement |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5578709A (en) | 1993-03-09 | 1996-11-26 | Middlesex Sciences, Inc. | Macromolecular microparticles and methods of production |
US5554730A (en) | 1993-03-09 | 1996-09-10 | Middlesex Sciences, Inc. | Method and kit for making a polysaccharide-protein conjugate |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
NL9401150A (nl) | 1994-07-12 | 1996-02-01 | Nederland Ptt | Werkwijze voor het aan een ontvangzijde aanbieden van een van een zendzijde afkomstig eerste aantal videosignalen, alsmede systeem, alsmede zender, alsmede netwerk, en alsmede ontvanger. |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
DE69529572T2 (de) | 1994-11-10 | 2003-06-18 | The University Of Kentucky Research Foundation, Lexington | Implantierbare wiederauffüllbare vorrichtung mit gesteuerter freisetzung zur verabreichung von arzneistoffen unmittelbar an einen inneren teil des körpers |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5739307A (en) * | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
US6156331A (en) | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
EP0877599B1 (en) | 1996-02-02 | 2003-03-26 | Alza Corporation | Sustained delivery of leuprolide using an implantable system |
US5976109A (en) | 1996-04-30 | 1999-11-02 | Medtronic, Inc. | Apparatus for drug infusion implanted within a living body |
DE69725747T2 (de) | 1996-08-23 | 2004-07-29 | Sequus Pharmaceuticals, Inc., Menlo Park | Liposome enthaltend cisplatin |
AU4907897A (en) | 1996-10-11 | 1998-05-11 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
EP0966267B1 (en) | 1996-10-15 | 2009-02-25 | Transave, Inc. | N-acyl phosphatidylethanolamine-mediated liposomal drug delivery |
US6395302B1 (en) | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
EP0842657A1 (en) | 1996-11-19 | 1998-05-20 | OctoPlus B.V. | Microspheres for controlled release and processes to prepare these microspheres |
ATE282092T1 (de) | 1997-06-11 | 2004-11-15 | Borean Pharma As | Trimerisierendes modul |
US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
US6399383B1 (en) | 1997-10-28 | 2002-06-04 | Maxygen, Inc. | Human papilloma virus vectors |
CN100388916C (zh) | 1997-12-22 | 2008-05-21 | 阿尔扎有限公司 | 用于控释药物传递装置的速率控制膜 |
ZA986627B (en) | 1997-12-30 | 1999-03-05 | Alza Corp | Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
AU2001262992A1 (en) | 2000-05-10 | 2002-02-18 | University Of Kentucky Research Foundation | System and method for intranasal administration of opioids |
KR100867392B1 (ko) | 2000-08-15 | 2008-11-06 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 마이크로입자 |
FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
US6436386B1 (en) | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
CN1114690C (zh) | 2001-05-15 | 2003-07-16 | 乔良 | 乳头瘤假病毒及其制备方法 |
US7812120B2 (en) | 2003-03-21 | 2010-10-12 | Par Pharmaceutical, Inc. | Nasal calcitonin formulations containing chlorobutanol |
KR20060095568A (ko) * | 2003-10-20 | 2006-08-31 | 엔에스진 에이/에스 | 파킨슨병의 생체내 유전자 요법 |
DK1694354T3 (da) * | 2003-11-27 | 2009-10-26 | Develogen Ag | Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin |
EP1750756A2 (en) | 2004-05-10 | 2007-02-14 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
US7790446B2 (en) | 2005-02-11 | 2010-09-07 | Kosagen Cell Factory Oü | Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products |
US8034572B2 (en) * | 2006-08-30 | 2011-10-11 | Mart Saarma | Receptor for GDNF family ligands |
WO2008049897A1 (en) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
CN104288775A (zh) * | 2007-11-05 | 2015-01-21 | 伊沃泰克国际有限公司 | 用于药物用途的neurturin缀合物 |
-
2010
- 2010-10-28 CN CN2010800543012A patent/CN102695723A/zh active Pending
- 2010-10-28 ES ES14165977.1T patent/ES2632431T3/es active Active
- 2010-10-28 WO PCT/US2010/054419 patent/WO2011053675A2/en active Application Filing
- 2010-10-28 NZ NZ599543A patent/NZ599543A/en not_active IP Right Cessation
- 2010-10-28 EP EP14165977.1A patent/EP2774935B8/en active Active
- 2010-10-28 BR BR112012009801A patent/BR112012009801A8/pt not_active IP Right Cessation
- 2010-10-28 CA CA2778678A patent/CA2778678A1/en not_active Abandoned
- 2010-10-28 AU AU2010313456A patent/AU2010313456A1/en not_active Abandoned
- 2010-10-28 JP JP2012537030A patent/JP2013509422A/ja active Pending
- 2010-10-28 EP EP10827453.1A patent/EP2493918A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN102695723A (zh) | 2012-09-26 |
CA2778678A1 (en) | 2011-05-05 |
EP2774935B1 (en) | 2017-04-19 |
WO2011053675A3 (en) | 2011-08-25 |
EP2774935A1 (en) | 2014-09-10 |
AU2010313456A1 (en) | 2012-05-17 |
JP2013509422A (ja) | 2013-03-14 |
NZ599543A (en) | 2014-02-28 |
EP2774935B8 (en) | 2017-06-21 |
EP2493918A2 (en) | 2012-09-05 |
ES2632431T3 (es) | 2017-09-13 |
BR112012009801A2 (pt) | 2016-08-09 |
EP2493918A4 (en) | 2013-04-10 |
WO2011053675A2 (en) | 2011-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0911385A2 (pt) | mutantes fgf21 e seus usos | |
UY32607A (es) | Mutantes de fgf21 y usos del mismo | |
BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
BR112018008766A2 (pt) | variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos | |
WO2009142460A3 (en) | Antibody-peptide fused synergibody | |
BRPI0921830A8 (pt) | Composição para tratamento bucal compreendendo sílica fundida | |
BRPI0807132A2 (pt) | enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas | |
BR112016025263A2 (pt) | vetores de avv para terapia genética retiniana e do snc | |
MX2008001865A (es) | Proteinas de fusion de albumina. | |
EA201590910A1 (ru) | Белки на основе структурного домена фибронектина, связывающие pcsk9 | |
EA201000559A1 (ru) | Композиции и способы применения антител к склеростину | |
BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
EA201990619A1 (ru) | Fgf21 мутанты и их применение | |
MX2013001977A (es) | Proteinas osteogenicas de diseño. | |
MX360085B (es) | Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. | |
CL2009000862A1 (es) | Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer. | |
WO2011063320A3 (en) | Recombinant filaggrin polypeptides for cell importation | |
EP2282738A4 (en) | PROMOTING AXONE REGENERATION IN THE CENTRAL NERVOUS SYSTEM OF THE ADULT BY CONTROLLING PROTEIN TRANSLATION | |
BR112015003399A2 (pt) | métodos e composições úteis para melhorar a saúde óssea e articular | |
CL2007003190A1 (es) | Compuestos derivados de arilsulfonil-pirrolidinas; procedimiento de obtencion; composicion farmaceutica; y uso en la prevencion o tratamiento de enfermedades tales como psicosis, depresion, alzheimer, entre otras. | |
BR112012009801A8 (pt) | Polipeptídeo neurturina e variante de neurturina | |
BRPI1011961A2 (pt) | agente para o tratamento ou prevenção de doenças associadas com a atividade de fatores neurotróficos. | |
BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
BR112015014718A2 (pt) | métodos de uso de cromatografia de troca iônica para controlar níveis de glicoformas ricas em manose | |
GB0517466D0 (en) | Diagnostic assay and therapeutic treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: NTF THERAPEUTICS, INC. (US) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |